Molecular determinants of response to PD-L1 blockade across tumor types
|Study ID||Alternative Stable ID||Type|
Study Datasets 4 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Clinical data from IMvigor210, POPLAR, IMmotion151: Clinical data include demographics, tumor type, PD-L1 IHC, tumor mutation burden, objective response rate, overall survival and progression free survival for 611 patients across IMvigor210, POPLAR and IMmotion150. Clinical data from PCD4989g: Clinical data include tumor type, PD-L1 expression and objective response rate for 206 patients from PCD4989g.
RNAseq FASTq files from 817 bulk pre-treatment tumors from three indications (mUC, NSCLC and RCC) across three phase II (IMvigor210, POPLAR, IMmotion150) and a phase I (PCD4989g) clinical trials.
|Illumina HiSeq 4000||817|
Whole exome sequencing FASTq files from 469 pre-treatment tumors from IMvigor210, POPLAR and IMmotion150, with matched PBMC samples.
|Illumina HiSeq 4000||834|
Matrices of TPM-normalized counts from RNAseq data for the three phase II clinical trials (IMvigor210, POPLAR, IMmotion150) and the phase I clinical trial PCD4989g.